Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report published on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on MRNS. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Royal Bank of Canada dropped their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Finally, Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $0.54 on Friday. The company has a market capitalization of $29.69 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The stock’s 50 day simple moving average is $0.33 and its 200 day simple moving average is $1.04. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $11.26.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals during the second quarter worth about $28,000. AQR Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $64,000. World Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals in the third quarter valued at $104,000. Finally, Squarepoint Ops LLC acquired a new position in Marinus Pharmaceuticals during the second quarter worth $206,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.